User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

Scientific highlights: 2013 Asia-Pacific Cardiology Symposium From hypertension to heart failure - Interruption of the cardiovascular continuum

Scientific highlights: 2013 Asia-Pacific Cardiology Symposium From hypertension to heart failure - Interruption of the cardiovascular continuum
  • Cardiometabolic
  • Hypertension

Resource type

Publication

Tags

Beta-blockers in cardioprotection
Patient compliance
Compliance
Adherence
Stroke
anticoagulants

The conference “From hypertension to heart failure – Interruption of the cardiovascular continuum” organised by EXCEMED (formerly Serono Symposia International Foundation) and held in Hanoi, Vietnam on 6-7 April, covered a broad spectrum from the value of beta-blockers, problems of adherence and non-medical approaches to reduce hypertension. The key slides from the meeting and the detailed medical report is available to all registered users of the EXCEMED website.

Amongst the presentations was Professor Brian Tomlinson talking on the cardio-protective effects of beta-blockers, with a reduction in morbidity and mortality when they are used in hemodynamically stable cases. Professor Struijker Boudier suggested that, despite the value of such basic medication, the problem of adherence in the treatment of hypertension is serious. Single pill fixed dose drugs combination therapy can help to improve this.

Professor Mahn Hung presented preliminary results on two novel non-medical approaches. This was based on evidence of sympathetic hyperactivation and baroflex depression can be managed to reduce reducing uncontrolled and resistant hypertension.

Prevention of stroke by novel anticoagulants such as debigatran and rivaroxaban was outlined by Professor Hiremath. In comparison with traditional anticoagulants such as warfarin the newer anti thrombotics have many qualities such as faster action and lower risk of bleeding. The expense is a major negative factor together with not having a real antidote.

Terms of use

This is a copyrighted resource for the sole purpose of education. Resource may be used for classroom training only and must remain as is, including the branding and EXCEMED logo. It is backed by a publishing license, signed by the author.

Target audience
Cardiologists, internists, Healthcare professionals, General practitioners
EBAC
by Excemed
Cardiometabolic